Luqa Pharmaceuticals, a China specialty care company that markets solutions in dermatology and other specialty areas, has completed a $15 million round of fund raising. The new financing was led by Morningside Ventures. Proceeds will be used to expand, develop and fund on-going operations and commercialization of Luqa’s product range.

Luqa has been able to record strong growth since the launch of its first product in 2013. Luqa has now launched an additional eight products, with three more launches expected in 2015. Luqa has become a reference company in China’s derma-aesthetic space offering medical, corrective and aesthetic product lines, which are used mainly by physicians to enhance patients’ appearance.

“The financing provides capital necessary to substantially grow, providing unique physician driven solutions for Chinese patients,” said Robert Braithwaite, chief executive officer, Luga. “We continue to strive to build a modern healthcare model, well adapted to today’s China needs, based on strengthening the relationship between patients and providers through education and information.”

“The proven track record of Luqa’s team, together with its portfolio and distribution partnerships, create a very compelling future,” said Michael Xue, Morningside Ventures.